The use of conditionally replicating adenoviruses offers an attractive complementary treatment strategy for localized prostate cancer. We have produced a replicating adenovirus, Ad[I/PPT-E1A], where E1A gene expression is controlled by a recombinant regulatory sequence designated PPT. The PPT sequence comprises a PSA enhancer, a PSMA enhancer and a T-cell receptor g-chain alternate reading frame protein promoter, and it is shielded from transcriptional interference from adenoviral backbone sequences by an H19 insulator. Ad[I/PPT-E1A] yields prostate-specific E1A protein expression, viral replication and cytolysis in vitro. Furthermore, Ad[I/PPT-E1A] considerably regresses the growth of subcutaneous LNCaP prostate cancer tumors in nude mice. Importantly, the viral replication and cytolytic effect of Ad[I/PPT-E1A] are independent of the testosterone levels in the prostate cancer cells. This may be beneficial in a clinical setting since many prostate cancer patients are treated with androgen withdrawal. In conclusion, Ad[I/PPT-E1A] may prove to be useful in the treatment of localized prostate cancer.
Introduction
Prostate cancer is a leading cause of cancer-related death among men in the Western World. 1 The American Cancer Society estimated that about 230 110 men would be diagnosed and 29 900 men would die from this disease in the USA in 2004. 2 The standard therapies for localized prostate cancer include radical prostatectomy and external beam irradiation, under some circumstances incorporating hormonal therapy. 3 While these therapies are relatively effective in the short term, a significant proportion of patients who initially present with localized disease ultimately relapse. 4 The use of conditionally replicating adenoviruses (CRADs) offers an attractive strategy for cancer treatment, since it allows for selective replication of viruses in defined target cells and thereby augments the spread of therapeutic gene expression. 5 In order to make CRADs tumor-or tissue-specific, two strategies are employed. One is to mutate adenoviral genes to obtain strains that selectively replicate in tumor cells. One example is the dl1520 adenovirus (also called ONYX-15), which lacks the E1B-55K protein that binds to p53 and blocks its apoptotic activity. 6 In cancer cells, the p53 pathway is often dysfunctional, leading to selective replication of ONYX-15 in such cells. However, several reports have indicated that ONYX-15 can replicate in cancer cells independently of the p53 status. 7, 8 Clinical trials with ONYX-15 have demonstrated good safety profiles and therapeutic effects on tumors.
9,10 A replication-competent E1B-attenuated adenovirus similar to ONYX-15 that contains a cytosine deaminase/herpes simplex virus-1 thymidine kinase fusion gene (called Ad5-CD/TKrep) was used in a phase I trial for localized prostate cancer with demonstrated safety and therapeutic effects. 11, 12 Another example of a well-studied CRAD with genetic modification is the AdD24 virus, which selectively replicates in tumor cells with a dysfunctional pRB pathway. 13 The second strategy involves the use of tumor-or tissue-specific promoters to drive selective genes, such as E1A, that are necessary for the viral replication. Several oncolytic adenoviruses with tissue-or tumor-specific promoters, such as human telomerase reverse transcriptase, cyclooxygenase-2, secretary leukoprotease inhibitor, alfa-fetoprotein, human kalikrein 2 and prostate-specific antigen (PSA) have been reported. [14] [15] [16] [17] [18] A prostate-specific CRAD using promoter and enhancer elements from PSA to control the E1A gene expression was used in a phase I clinical trial with demonstrated safe intraprostatic delivery and therapeutic effects. 19 We have recently cloned the promoter from the T-cell receptor g-chain alternate reading frame protein (TARP). 20 Furthermore, we have produced an adenoviral vector with a recombinant regulatory sequence designated PPT, comprising the TARP promoter, PSMA enhancer and PSA enhancer, which is shielded from interfering adenoviral sequences by the mouse H19 insulator. 21 The insulator-shielded PPT adenoviral vector yields high and prostate-specific transgene expression both in the presence and absence of testosterone. 21 Intravenous administration of the adenovirus in nude mice with an orthotopic human prostate tumor, PC-346C, revealed an absolute prostate tumor selectivity and an activity comparable to the CMV promoter. 21 In the present study, we have generated a prostatespecific CRAD in which the E1A gene is under the control of the insulator-shielded PPT sequence (Ad[I/PPT-E1A]). Our results show that Ad[I/PPT-E1A] is effective in generating specific oncolytic effect in prostate cancer cells in vitro. Furthermore, it regresses the growth of LNCaP tumors in nude mice. These data suggest that Ad[I/PPT-E1A] could be a selective and potent CRAD for the treatment of localized prostate cancer.
Materials and methods

Cell lines
The prostate adenocarcinomas LNCaP and PC-346C, the colon carcinoma HT29 and the glioma U343 were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES and 1 mM sodium pyruvate. The transformed embryonic retina 911 and the human foreskin fibroblast 1064SK were cultured in DMEM supplemented with 5% FBS and 2 mM L-glutamine. The aortic endothelial cells HAEC were cultured in Medium 200 (Cascade Biologics, Portland, OR) supplemented with Low Serum Growth Supplement Kit (Cascade Biologics). Steroid-depleted cell culture medium was RPMI 1640 supplemented with 5% charcoal/dextran-treated FBS (Hyclone, Logan, UT), 2 mM L-glutamine, 10 mM HEPES and 1 mM sodium pyruvate. Synthetic testosterone R1881 was from NEN Life Sciences, Boston, MA. All cell culture reagents, except when stated differently, were from Invitrogen, Carlsbad, CA.
Recombinant adenoviral vectors
Adenoviruses were constructed using the E1/E3-deleted AdEasy system 22 according to the manufacturer's instructions. The pAdEasy1, pShuttle-CMV and pShuttle vectors were kind gifts from Dr B Vogelstein (Johns Hopkins, Baltimore, MD). The pShuttle containing the H19 insulator/PPT promoter cassette (pShuttle-I/PPT) has been described earlier. 21 The human serotype 2 adenovirus E1A coding sequence was PCR amplified from pKGO-170, a kind gift from Dr G Akusja¨rvi (Uppsala University, Uppsala, Sweden), using the following primers: E1A.F1 forward (5 0 -CAAGGTC-GACCTCTTGAGTGCCAG-3 0 ) and E1A.R1 reverse (5 0 -AGCCGTCGACCATTTAACACGCCA-3 0 ) (SalI restriction enzyme sites are underlined). E1A was sequenced (Big Dye; Perkin-Elmer, Norwalk, CT) and inserted in the , IN) , 0.1% SDS, 1 mM Pefabloc SC (Roche)). Protein concentrations were determined using the Gelcode Blue Stain reagent (Pierce, Rockford, IL). Total protein extracts were resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). The membranes were probed with a mouse monoclonal anti-E1A antibody (M73, Neomarkers Inc., Freemont, CA) and a goat polyclonal anti-b-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The secondary antibodies were POD-conjugated anti-mouse/rabbit (Roche) and horseradish peroxidase (HRP)-conjugated donkey anti-goat (Santa Cruz). The blots were visualized by using the BM Chemiluminescence Western Blotting kit (Roche) for the POD-conjugated antibody and the Western Blotting Luminol Reagent (Santa Cruz) for the HRP-conjugated antibody according to the manufacturers' instructions. In vitro viral replication assay Cells were plated at 6 Â 10 5 cells/well in six-well plates, incubated overnight and transduced with Ad[I/PPT-E1A] or Ad[CMV-E1A] at an MOI of 5 PFU/cell. At 2 h after transduction, fresh culture medium or steroid-depleted medium with or without 10 mM R1881 was added to the transduced cells. The cells were cultured for 72 h. Cell lysates were prepared by four cycles of freezing and thawing. Serial dilutions of the lysates were titrated on 911 cells using a standardized plaque assay. (Figure 6a) . At day 27, one of the mice was completely tumor-free. In contrast, mice injected with Ad [Mock] failed to show an inhibition of tumor growth, and at day 27, one of the mice had to be killed due to a large tumor mass. To verify the E1A expression in vivo, mice were killed 9 days after adenovirus injection and total RNA was isolated from the tumors and subjected to real-time PCR. As expected, E1A mRNA expression was only detected in tumors from mice injected with Ad[I/PPT-E1A], while no E1A mRNA expression was detected in tumors from mice injected with Ad[Mock] (Figure 6b ).
Cell viability assay
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Discussion
We have previously reported that a recombinant adenoviral vector with the PPT sequence, shielded from interfering adenoviral sequences by the mouse H19 insulator, yields high and prostate-specific transgene expression both in cell cultures and when human prostate tumors, PC-346C, were grown orthotopically in nude mice. 21 In this study, we constructed a novel prostatespecific CRAD, Ad[I/PPT-E1A], whose replication is under the control of the H19 insulator-shielded PPT promoter. 23, 24 between the PPT expression cassette and the LITR/E1A enhancer, which restores the PPT activity in prostate cancer cells and protects it from transcriptional interference of adenoviral sequences. This is the first example to our knowledge where the H19 insulator has been used in a CRAD. Other groups using tumor-or tissue-specific promoters in a CRAD have solved the specificity by inserting a polyA termination signal in between the LITR/E1A enhancer and the expression cassette 25 or by deleting large parts of the E1A promoter/enhancer region upstream of E1A. 26 Other CRADs with prostate-specific promoters have been reported. 18, [27] [28] [29] The CV706 adenovirus, where the E1A gene is under the control of the PSE sequence (the minimal PSA promoter with the upstream PSA enhancer), was used in a phase I clinical trial with a demonstrated good safety profile and therapeutic effects. 19 The PSA promoter is, however, dependent on a functional androgen receptor pathway. Since prostate cancer patients are often treated by androgen withdrawal, it may be beneficial to use a CRAD that is not dependent on a high testosterone level. Recently, a CRAD against prostate cancer has been reported where the E1A gene is under the control of the PSMA enhancer. 29 The PSMA enhancer-controlled CRAD showed good efficacy at low levels of testosterone and it could theoretically be used for prostate cancer patients treated with androgen withdrawal. However, the transcriptional activity of the PSMA enhancer is downregulated at physiological levels of testosterone, which limits the use of the PSMA enhancer-controlled CRAD in patients that are not subject to androgen withdrawal. We have shown that Ad[I/PPT-E1A] yields prostate-specific virus replication and cell cytotoxicity independently on the testosterone level. To our knowledge, the Ad[I/PPT-E1A] is the first promoter-specific CRAD against prostate cancer with an oncolytic activity that is independent on the hormonal status of the prostate cancer cells.
The cell killing efficacy can be improved in many ways such as combining the oncolytic adenovirus effect with radiotherapy or chemotherapy. Clinical trials have shown that the combination of ONYX-15 virus and chemotherapy elicits a stronger antitumor response against head and neck cancer than ONYX-15 or chemotherapy alone. 30 Another way to increase the efficacy of CRADs is to arm them with therapeutic genes, such as HSV-TK, TRAIL and endostatin. [31] [32] [33] The Ad5-CD/TKrep-replicating adenovirus was used in a phase I clinical trial for localized prostate cancer, where the oncolytic therapeutic effect is combined with double-suicide gene therapy and conventional external beam radiation therapy. The safety of the trimodal therapy is good with demonstrated therapeutic effects. 12 The E3 region of the adenovirus is dispensable for viral replication in vitro and is often deleted from the adenoviral vectors used in gene therapy. However reinsertion of the E3 region, in whole or part, has been reported to enhance the cell killing efficacy of replicating adenoviruses. 28, 34 Another way to increase the antitumor effects is to use a CRAD in combination with a replication-defective adenovirus that is expressing a therapeutic gene. The transduction rate and the therapeutic efficacy of the replication-defective adenovirus can then be increased by the E1A proteins delivered by the CRAD. 35 In summary, we report herein a novel CRAD for prostate cancer, in which the E1A coding sequence is controlled by the H19 insulator-shielded recombinant PPT transcriptional regulatory sequence. The resultant Ad[I/PPT-E1A] virus demonstrates absolute prostate specificity in vitro and in vivo, and importantly, it is active both in the presence and absence of testosterone. We therefore believe that the Ad[I/PPT-E1A] virus will prove to have therapeutic potential for patients with localized prostate cancer.
